+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
From
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • February 2021
  • 43 pages
From
From
Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2020 - Product Thumbnail Image

Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 pages
From
From
Muscular Dystrophy - Pipeline Review, H2 2020 - Product Thumbnail Image

Muscular Dystrophy - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 287 pages
From
Duchenne Muscular Dystrophy - Pipeline Review, H2 2020 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 413 pages
From
From
Global Coronavirus Partnering 2014-2021 - Product Thumbnail Image

Global Coronavirus Partnering 2014-2021

  • Report
  • April 2021
  • 650 pages
From
Loading Indicator
adroll